Provided herein are methods for selecting a population of cells expressing a target polypeptide. In some aspects, the disclosure provides methods for sorting and selecting populations of transfected host cells based on their early expression of a selectable polypeptide. In certain embodiments, the sorting is performed using fluorescence-activated cell sorting or magnetic-activated cell sorting based on the selectable polypeptide. Such selection methods can be further utilized to generate clonal populations of producer cells, e.g. for large-scale manufacturing of a target polypeptide of interest.

The invention relates to a device (1) for preparing a cell suspension comprising an enzyme reservoir (10), a first purification compartment (20) for receiving a first purification material (P1), wherein the first purification compartment (20) is in fluid connection or can be brought into fluid connection with the enzyme reservoir (10), a syringe (40) comprising a barrel (41) defining a barrel compartment (45) and a piston (42) which is movably arranged in the barrel compartment (45), wherein the syringe (40) comprises a syringe inlet (43) connected to the barrel compartment (45), wherein the syringe inlet (43) is in fluid connection or can be brought into fluid connection with the first purification compartment (20), and wherein the syringe (40) comprises a syringe outlet (44), and wherein the device (1) comprises a flow path from the enzyme reservoir (10) via the first purification compartment (20) to the syringe inlet (43). Also provided herein are methods for preparing a cell suspension.

The present invention relates generally to methods for stimulating T cells, and more particularly, to methods to eliminate undesired (e.g., autoreactive, alloreactive, pathogenic) subpopulations of T cells from a mixed population of T cells, thereby restoring the normal immune repertoire of said T cells. The present invention also relates to compositions of cells, including stimulated T cells having restored immune repertoire and uses thereof.

Systems and methods for sorting T cells are disclosed. Autofluorescence data is acquired from individual cells. An activation value is computed using one or more autofluorescence endpoints as an input. The one or more autofluorescence endpoints includes NAD(P)H shortest fluorescence lifetime amplitude component (.sub.1).

The present invention relates to a method for ex vivo photodynamic treatment of cells. A cell preparation is incubated in a first medium having 5 M or less of a photosensitive compound. A population of cells in the cell preparation retains the photosensitive compound, for example, a salt of 2-(4,5-dibromo-6-amino-3-imino-3H-xanthen-9-yl)-benzoic acid methyl ester. The first medium is then replaced with an extrusion medium to remove the photosensitive compound. The cell preparation is then illuminated in the extrusion medium to selectively kill the population of cells retaining the photosensitive compound, thereby creating an illuminated cell preparation.

The present invention is directed to the use of microfluidics in the preparation of cells and compositions for therapeutic uses.

The present invention relates to methods for the specific separation of target cells from a biological sample, comprising specific binding of the target cells to phase-change hydrogel compositions and separation of respective cell-hydrogel complexes by counter-current centrifugation.

An object of the present invention is to provide a separation substrate having a high megakaryocyte blocking rate and a high platelet permeation rate, and a cell separation filter and a method for producing a platelet which use the same. The separation substrate of the present invention is a separation substrate including non-woven fabric for separating a platelet from a cell suspension containing a megakaryocyte and the platelet, in which an average pore diameter of the separation substrate is 2.0 m to 15.0 m, and a thickness of the separation substrate is 10 m to 500 m.

Methods of using CD37 agents, including, but not limited to, antibodies and immunoconjugates, that bind to CD37 to deplete B-cells (e.g., non-cancerous B-cells) and methods of treating autoimmune and inflammatory diseases are further provided.

Provided are methods of making innate immune cell compositions containing gamma.delta () T cells and/or Natural Killer (NK) cells, and the resulting compositions and related products of manufacture and kits for use in cancer and infectious disease therapy. The methods provided herein permit tailoring of the relative amounts of gamma.delta () T cells and Natural Killer (NK) cells in the compositions, for cellular therapies against a wide variety of cancers and infectious diseases. The resulting compositions can further be used to generate compositions containing either NK cells alone or gamma.delta T cells alone, for immune cellular therapies. The compositions provided herein also can be genetically altered: the gamma delta T cells and Natural Killer cells are modified to express chimeric antigen receptors (CARS) or exogenous T cell receptors (TCRs), which can be used to target any cell surface molecule either directly or indirectly, e.g., a marker on a cancer cell or an infected cell.